Abstract 5795
Background
AR-inhibition with Enzalutamide may be an attractive alternative for 1L treatment of men with hormone-sensitive prostate cancer compared to androgen deprivation therapy (ADT). There is an unmet need for robust, reproducible imaging technology allowing accurate quantification and qualification of bone plus soft tissue metastases and assessment of early tumour responses to novel agents. PET/CT or WB MRI imaging offer advantage over traditional bone and CT scans.
Methods
Sixty patients with metastatic hormone-sensitive PC were included in this prospective cohort study. Patients received Enzalutamide 160 mg once daily until progression of disease. Imaging tests were performed at baseline and bone scintigraphy and CT repeated at 3 month intervals, 18F-choline PET/CT at 2 weeks, 2, 6, 9 and 12 months and WB-MRI at 6 and 12 months. Enumeration of circulating tumor cells and quality of life assessments were secondary outcomes.
Results
Sixty patients with a median age of 72 yrs (range 57 − 85) and a median PSA of 62.8 μg/L (range 3-622) were enrolled. This study is ongoing; all of the first 50 patients experienced a ≥ 50% PSA decline and 49 a ≥ 90% PSA decline. Choline-PET imaging and WB MRI were more frequently able to detect metastases and measure favorable responses than bone scan or CT thorax and abdomen. Investigator and central review of all imaging results are ongoing. Treatment was well tolerated.
Conclusions
18F-choline PET/CT and WB-MRI were superior in detection of bone and lymph node metastases and 18F-choline PET/CT was useful for early response detection already at 2 weeks. Based on results both 18F-choline-PET and WB MRI imaging have great clinical utility in aiding clinicians treating men with hormone-sensitive metastatic prostate cancer.
Clinical trial identification
NCT02815033.
Editorial acknowledgement
Legal entity responsible for the study
European Uro-Oncology Group (EUOG).
Funding
Astellas Pharma.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract